Biotechs Rise on Bet Medivation Losers Will Look to Next Deal

  • BioMarin, Tesaro, Incyte, Clovis shares all gain Monday
  • Pfizer beat out Sanofi, others in $14 billion Medivation deal

Pfizer Claims Pharmaceutical's Latest Big Prize

For losers in the $14 billion bidding war over drugmaker Medivation Inc., the best cure for the mergers and acquisitions blues may be to go shopping.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.